Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease.

Immune respons Virology

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
19 Nov 2021
Historique:
received: 07 05 2021
revised: 24 08 2021
accepted: 30 09 2021
pubmed: 12 10 2021
medline: 12 10 2021
entrez: 11 10 2021
Statut: ppublish

Résumé

The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19.

Identifiants

pubmed: 34632328
doi: 10.1016/j.isci.2021.103219
pii: S2589-0042(21)01187-1
pmc: PMC8492382
doi:

Types de publication

Journal Article

Langues

eng

Pagination

103219

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

L.A.S., Y.P., B.W.B., P.P.M., L.S., and S.K.W. are co-inventors on a United States Provisional Application No. 63/196,489 entitled “ENGINEERED NEWCASTLE DISEASE VIRUS VECTOR AND USES THEREOF”, which was filed June 3, 2021.

Références

N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):13996-4000
pubmed: 22891297
J Gen Virol. 2019 Dec;100(12):1593-1594
pubmed: 31609197
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
J Gen Virol. 2005 Aug;86(Pt 8):2269-2274
pubmed: 16033974
Eur J Clin Invest. 2021 May;51(5):e13554
pubmed: 33768536
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
J Vet Diagn Invest. 2011 Jul;23(4):637-56
pubmed: 21908305
J Clin Oncol. 2002 May 1;20(9):2251-66
pubmed: 11980996
Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
J Virol. 2008 Sep;82(18):9303
pubmed: 18755681
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
EBioMedicine. 2020 Dec;62:103132
pubmed: 33232870
J Virol. 2006 Nov;80(21):10652-62
pubmed: 17041223
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
Infect Genet Evol. 2020 Oct;84:104493
pubmed: 32768565
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Emerg Infect Dis. 2020 Sep;26(9):2005-2015
pubmed: 32437316
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Mol Ther Methods Clin Dev. 2017 Oct 16;9:181-191
pubmed: 29556508
J Gen Virol. 2015 Jan;96(Pt 1):40-45
pubmed: 25274858
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Pathogens. 2020 Jul 29;9(8):
pubmed: 32751194
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8203-8
pubmed: 16717196
Vaccines (Basel). 2020 Dec 17;8(4):
pubmed: 33348607
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Curr Protoc Microbiol. 2006 Jun;Chapter 15:15F.2.1-15F.2.18
pubmed: 18770579
Immunity. 2016 Jun 21;44(6):1379-91
pubmed: 27287409
Virulence. 2021 Dec;12(1):507-508
pubmed: 33494661
Emerg Infect Dis. 2020 Aug;26(8):1926-1928
pubmed: 32396504
Virchows Arch. 2020 Sep;477(3):359-372
pubmed: 32642842
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Science. 2021 Jan 22;371(6527):329-330
pubmed: 33479129
Front Immunol. 2020 Oct 07;11:576622
pubmed: 33117378
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
Mucosal Immunol. 2021 Mar;14(2):305-316
pubmed: 33244161
J Virol. 1998 Feb;72(2):891-9
pubmed: 9444980
Methods Mol Biol. 2020;2099:205-220
pubmed: 31883098
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Front Immunol. 2019 Jul 17;10:1605
pubmed: 31379823
New Microbes New Infect. 2021 Sep;43:100929
pubmed: 34336227
J Biol Chem. 2021 Jan-Jun;296:100111
pubmed: 33229438
Am J Respir Cell Mol Biol. 2020 Dec;63(6):856-859
pubmed: 32897757
Int J Lab Hematol. 2020 Jun;42 Suppl 1:11-18
pubmed: 32311826
J Virol Methods. 2014 Jun;202:28-33
pubmed: 24626064
J Virol. 2005 Nov;79(21):13275-84
pubmed: 16227250
Crit Care. 2020 Nov 16;24(1):647
pubmed: 33198786
Viruses. 2016 Jul 04;8(7):
pubmed: 27384578
J Virol. 2020 Oct 14;94(21):
pubmed: 32788194
MMWR Morb Mortal Wkly Rep. 2021 Aug 06;70(31):1059-1062
pubmed: 34351882
EBioMedicine. 2020 Aug;58:102887
pubmed: 32736307
Vaccine. 2010 Dec 10;29(1):17-25
pubmed: 21034822
Vaccines (Basel). 2020 Nov 13;8(4):
pubmed: 33202961
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
One Health. 2020 Feb 24;9:100124
pubmed: 32195311
Nature. 2020 Apr;580(7805):578-580
pubmed: 32273621
Emerg Infect Dis. 2020 Jun;26(6):1320-1323
pubmed: 32125269
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
J Virol. 2007 Nov;81(21):11560-8
pubmed: 17715243
Virol J. 2020 Jan 31;17(1):16
pubmed: 32005267
Int J Lab Hematol. 2021 Apr;43(2):160-168
pubmed: 33264492
Adv Exp Med Biol. 2017;972:87-101
pubmed: 27722960
J Virol. 2000 Jun;74(11):5101-7
pubmed: 10799584
Biochim Biophys Acta. 1989 Nov 30;999(2):171-5
pubmed: 2597705
N Engl J Med. 1964 Sep 24;271:645-51
pubmed: 14170843
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Cancer Detect Prev. 1993;17(6):619-27
pubmed: 8275514
Trends Immunol. 2016 Dec;37(12):844-854
pubmed: 27793570
Lancet. 2020 Nov 7;396(10261):1467-1469
pubmed: 32971042
J Med Virol. 2020 Sep;92(9):1511-1517
pubmed: 32437052
Nature. 2020 Aug;584(7819):22-25
pubmed: 32760050
Nature. 2020 Jun;582(7813):467-468
pubmed: 32546810
Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):1-6
pubmed: 14663646

Auteurs

Bryce M Warner (BM)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Lisa A Santry (LA)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Alexander Leacy (A)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Mable Chan (M)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Phuc H Pham (PH)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Robert Vendramelli (R)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Yanlong Pei (Y)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Nikesh Tailor (N)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Emelissa Valcourt (E)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Anders Leung (A)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Shihua He (S)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Bryan D Griffin (BD)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Jonathan Audet (J)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Marnie Willman (M)

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Kevin Tierney (K)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Alixandra Albietz (A)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Kathy L Frost (KL)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Jacob G E Yates (JGE)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Robert C Mould (RC)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Lily Chan (L)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Yeganeh Mehrani (Y)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Jason P Knapp (JP)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Jessica A Minott (JA)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Logan Banadyga (L)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

David Safronetz (D)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Heidi Wood (H)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Stephanie Booth (S)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.

Pierre P Major (PP)

Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.

Byram W Bridle (BW)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Leonardo Susta (L)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Darwyn Kobasa (D)

Zoonotic Diseases and Special Pathogens, Public Health Agency of Canada, Winnipeg, Canada.
Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.

Sarah K Wootton (SK)

Department of Pathobiology, University of Guelph, Guelph, Canada.

Classifications MeSH